Get 40% Off
🤯 This Tech Portfolio is up 29% YTD! Join Now to Get April’s Top PicksGet The Picks – Just 99 USD

BeiGene To Build Biologics Plant In China

Published 03/28/2017, 12:15 PM
Updated 03/09/2019, 08:30 AM

Fast-growing biotechnology company BeiGene Ltd. (NASDAQ:BGNE) recently announced that they will be constructing a new biologics manufacturing plant in Guangdong Province in China. This would make the project one of the biggest manufacturing ventures for the year.

The company, which would be working with the Guangzhou Development District, is set to build the state-of-the-art biologics manufacturing plant worth $330 million. The joint venture to construct the commercial-scale biologics facility will also be allocating funding for the research and development of biologic drug candidates in China.

Beigene, which is known for their focus on developing a portfolio of immuno-oncology, is set to compete with Western companies in the same field and will be prioritizing the production of high quality and large scale products that will be distributed not just in China but in the global markets as well.

“It is our strategic priority to secure high-quality large-scale manufacturing capacity based on the increasing biologics opportunity. We believe the joint venture will provide a valuable asset for our long-term growth,” said Beigene CEO John Oyler.

Beigene currently is developing PARP inhibitors, which can compete with Astrazeneca's (NYSE:AZN) Lynparza and Pfizer's (NYSE:PFE) latest Medivation.

“Biologics represent an important part of BeiGene’s overall R&D and manufacturing capabilities. This joint venture will enable BeiGene to keep pace with a growing demand for the development and use of biologics in China and global markets,” said BeigeneCo-founder and director Dr. Wang Xiaodong. Wang also serves as the Chairman of the Scientific Advisory Board of Beigene.

The company, which would be receiving $30 million from Beigene Hong Kong and another $150 million from the Guangzhou GET Technology Development Co. Ltd., would include an equity investment in cash from JV Company. An additional funding of $150 million will also be given to the manufacturing factory from a subsidiary of the JV company.

The announcement of the project has been received positively by both investors and the Chinese government who stated that the venture will help biotechnology in the area and therefore promote growth.

“We attach great importance to this project and believe that the successful introduction of BeiGene Biologics will transform Guangzhou Development District into a center for the innovative biopharmaceutical industry, promote the development of the biotechnology industry in the region, and provide a powerful driving force for economic transformation and upgrade. The government will provide strong support in funding, management service, and creating a good business environment,” said the Administrative Committee of Guangzhou Municipal Government and Guangzhou Development District.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.